Urinary Kidney Injury Biomarker Profiles in Healthy Individuals and After Nephrotoxic and Ischemic Injury
- Published on 01/08/2025
- Reading time: 7 min.
Sushrut S. Waikar 1, Robin Mogg 2, Amanda F. Baker 3, Gyorgy Frendl 4, Michael Topper 2, Scott Adler 5, Stefan Sultana 5, Runqi Zhao 1, Nicholas M. P. King 3, Steven P. Piccoli 6, John‐Michael Sauer 3, Steve Hoffmann 7, Irene Nunes 2, Frank D. Sistare 2
1
Department of Medicine and Section of Nephrology
Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center
Boston
Massachusetts
USA
2
Merck & Co., Inc.
Rahway
New Jersey
USA
3
Critical Path Institute
Tucson
Arizona
USA
4
Brigham and Women's Hospital
Boston
Massachusetts
USA
5
AstraZeneca
Cambridge
UK
6
Neoteric Consulting
Princeton
New Jersey
USA
7
Foundation for the National Institutes of Health
North Bethesda
Maryland
USA
Takeda Pharmaceuticals
Cambridge
Massachusetts
USA
Roche Diagnostic Solutions
Tucson
Arizona
USA
Greensboro
Georgia
USA
BridgeBio, Inc.
San Francisco
California
USA
Genmab, Inc.
Westfield
New Jersey
USA
Chapel Hill
North Carolina
USA
Abstract
Two observational studies were conducted to support an initiative to qualify translational kidney safety biomarkers as clinical drug development tools that identify tubular injury prior to changes in estimated glomerular filtration rate (eGFR). Normal healthy volunteers provided three morning spot urine collections over 4 weeks. Patients undergoing surgical resection and intrathoracic cisplatin for malignant pleural mesothelioma provided urine samples pre‐ and postoperatively...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Nephrology
Receive our newsletter to stay up to date with the latest news in Nephrology
